IP Library › Granted Patent US 12,527,344
Granted Patent B2
US 12,527,344 · App. 17/290,323 · Granted Jan 20, 2026

Aerosolizable formulation

Inventor: Ross Cabot (London, GB)
Assignee: NICOVENTURES TRADING LIMITED
A24B15/167
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,527,344
App. No.
17/290,323
Granted
Jan 20, 2026
Kind
B2
Abstract

An aerosolizable formulation comprising (i) water in an amount of at least 50 wt. % based on the aerosolizable formulation; (ii) nicotine; and (iii) one or more acids. A process for forming the aerosolizable formulation, the aerosolizable formulation contained within a container, and aerosolizing the aerosolizable formulation for inhalation by a user with an electronic aerosol provision system.

Claims (37)

1 . An aerosolizable formulation comprising

(i) water in an amount of at least 50 wt. % based on the aerosolizable formulation;

ii) nicotine;

(iii) one or more acids present in a total amount of from 0.2 to 1 wt. % based on the aerosolizable formulation; and

(iv) one or more cyclodextrins,

wherein the molar ratio of the one or more acids to the nicotine is from 5:1 to 1:1.

2 . The aerosolizable formulation according to claim 1 , wherein water is present in an amount of at least 75 wt. % based on the aerosolizable formulation.

3 . The aerosolizable formulation according to claim 1 , wherein water is present in an amount of at least 90 wt. % based on the aerosolizable formulation.

4 . The aerosolizable formulation according to claim 1 , wherein the nicotine is present in an amount of no greater than 1 wt. % based on the aerosolizable formulation.

5 . The aerosolizable formulation according to claim 4 , wherein the nicotine is present in an amount of from 0.01 to 0.6 wt. % based on the aerosolizable formulation.

6 . The aerosolizable formulation according to claim 1 , wherein at least 5 wt. % of the nicotine present in the formulation is in a protonated form.

7 . The aerosolizable formulation according to claim 1 , wherein at least 50 wt. % of the nicotine present in the formulation is in a protonated form.

8 . The aerosolizable formulation according to claim 1 , wherein at least 90 wt. % of the nicotine present in the formulation is in a protonated form.

9 . The aerosolizable formulation according to claim 1 , wherein the one or more acids is selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.

10 . The aerosolizable formulation according to claim 1 , wherein the one or more acids comprises citric acid.

11 . The aerosolizable formulation according to claim 1 , further comprising one or more flavors.

12 . The aerosolizable formulation according to claim 11 , wherein the one or more flavors are selected from the group consisting of (4-(para-) methoxyphenyl)-2-butanone, vanillin, γ-undecalactone, menthone, 5-propenyl guaethol, menthol, para-mentha-8-thiol-3-one and mixtures thereof.

13 . The aerosolizable formulation according to claim 11 , wherein the one or more flavors comprises menthol.

14 . The aerosolizable formulation according to claim 11 , wherein the one or more flavors are present in a total amount of no greater than 2 wt. % based on the aerosolizable formulation.

15 . The aerosolizable formulation according to claim 11 , wherein the one or more flavors are present in a total amount of from 0.01 to 1 wt. % based on the aerosolizable formulation.

16 . A process for forming an aerosol, the process comprising aerosolizing the aerosolizable formulation of claim 1 .

17 . The process according to claim 16 , wherein the aerosolizable formulation is aerosolized to form the aerosol at a temperature below 50° C.

18 . The process according to claim 16 , wherein aerosolizing the aerosolizable formulation comprises applying ultrasonic energy to the aerosolizable formulation.

19 . The aerosolizable formulation according to claim 1 , wherein the aerosolizable formulation is contained within a container.

20 . The contained aerosolizable formulation according to claim 19 , wherein the container is configured for engagement with an electronic aerosol provision system.

21 . An electronic aerosol provision system comprising:

(a) an aerosolizer for aerosolizing an aerosolizable formulation for inhalation by a user of the electronic aerosol provision system;

(b) a power supply comprising a cell or battery for supplying power to the aerosolizer; and

(c) the aerosolizable formulation, comprising:

(i) water in an amount of at least 50 wt. % based on the aerosolizable formulation;

(ii) nicotine;

(iii) one or more acids present in a total amount of from 0.2 to 1 wt. % based on the aerosolizable formulation; and

(iv) one or more cyclodextrins,

wherein the molar ratio of the one or more acids to the nicotine is from 5:1 to 1:1.

22 . A process for improving the sensory properties of an aerosolized nicotine formulation, the process comprising the steps of:

(a) providing an aerosolizable material comprising (i) water in an amount of at least 50 wt. % based on the aerosolizable material and (ii) nicotine; and

(b) incorporating into the aerosolizable material one or more acids and one or more cyclodextrins, wherein the one or more acids are present in a total amount of from 0.2 to 1 wt. % based on the aerosolizable formulation, and wherein the molar ratio of the one or more acids to the nicotine is from 5:1 to 1:1.

Priority Claims (1)
GB 1817863 · Nov 1, 2018 · national
Continuity (1)
Related Publication 20220000167A1 · Jan 6, 2022
References Cited (221)
US 4223292A · Morikawa et al. · 1980 [cited by applicant]
US 4588976A · Jaselli · 1986 [cited by applicant]
US 4735217A · Gerth et al. · 1988 [cited by applicant]
US 4922901A · Brooks et al. · 1990 [cited by applicant]
US 4945928A · Rose · 1990 [cited by applicant]
US 5060671A · Counts et al. · 1991 [cited by applicant]
US 5095921A · Losee et al. · 1992 [cited by applicant]
US 5179966A · Losee et al. · 1993 [cited by applicant]
US 5222362A · Maus et al. · 1993 [cited by applicant]
US 5322075A · Deevi et al. · 1994 [cited by applicant]
US 5530225A · Hajaligol · 1996 [cited by applicant]
US 5613505A · Campbell et al. · 1997 [cited by applicant]
US 5666978A · Counts et al. · 1997 [cited by applicant]
US 5692525A · Counts et al. · 1997 [cited by applicant]
US 5771845A · Pistien et al. · 1998 [cited by applicant]
US 6124579A · Steinhauser et al. · 2000 [cited by applicant]
US 6155268A · Takeuchi · 2000 [cited by applicant]
US 6671450B2 · Khan et al. · 2003 [cited by applicant]
US 7374063B2 · Reid · 2008 [cited by applicant]
US 8156944B2 · Han · 2012 [cited by applicant]
US 8948578B2 · Buchberger · 2015 [cited by applicant]
US 9333229B2 · Bjorncrantz · 2016 [cited by applicant]
US 9655890B2 · Hearn · 2017 [cited by examiner]
US 10449308B2 · Buchberger · 2019 [cited by applicant]
US 10602777B2 · Dickens et al. · 2020 [cited by applicant]
US 11064726B2 · Fujisawa et al. · 2021 [cited by applicant]
US 20010009660A1 · Delli Santi et al. · 2001 [cited by applicant]
US 20020113685A1 · Izaki et al. · 2002 [cited by applicant]
US 20030049025A1 · Neumann et al. · 2003 [cited by applicant]
US 20030159702A1 · Lindell et al. · 2003 [cited by applicant]
US 20030186474A1 · Haluzak et al. · 2003 [cited by applicant]
US 20040034068A1 · Warchol et al. · 2004 [cited by applicant]
US 20040096204A1 · Gerhardinger · 2004 [cited by applicant]
US 20040156792A1 · Tarara · 2004 [cited by applicant]
US 20040247302A1 · Toya et al. · 2004 [cited by applicant]
US 20050063686A1 · Whittle et al. · 2005 [cited by applicant]
US 20050211711A1 · Reid · 2005 [cited by applicant]
US 20050241656A1 · Kennison · 2005 [cited by applicant]
US 20050268911A1 · Cross et al. · 2005 [cited by applicant]
US 20070031343A1 · Bonfour et al. · 2007 [cited by applicant]
US 20070074734A1 · Braunshteyn et al. · 2007 [cited by applicant]
US 20070155255A1 · Galauner et al. · 2007 [cited by applicant]
US 20070267033A1 · Mishra et al. · 2007 [cited by applicant]
US 20080047956A1 · Dudman · 2008 [cited by applicant]
US 20080138399A1 · Gonda · 2008 [cited by applicant]
US 20080216828A1 · Wensley et al. · 2008 [cited by applicant]
US 20080286340A1 · Andersson et al. · 2008 [cited by applicant]
US 20090126745A1 · Hon · 2009 [cited by applicant]
US 20090220222A1 · Rabin et al. · 2009 [cited by applicant]
US 20090272379A1 · Thorens et al. · 2009 [cited by applicant]
US 20100126520A1 · Clayton · 2010 [cited by applicant]
US 20110155153A1 · Thorens et al. · 2011 [cited by applicant]
US 20110226236A1 · Buchberger · 2011 [cited by applicant]
US 20130081623A1 · Buchberger · 2013 [cited by applicant]
US 20130192623A1 · Tucker et al. · 2013 [cited by applicant]
US 20140182608A1 · Egoyants et al. · 2014 [cited by applicant]
US 20150030317A1 · Bayer et al. · 2015 [cited by applicant]
US 20150040925A1 · Saleem et al. · 2015 [cited by applicant]
US 20150059780A1 · Davis et al. · 2015 [cited by applicant]
US 20160157521A1 · Woodcock et al. · 2016 [cited by applicant]
US 20160198759A1 · Kuntawala et al. · 2016 [cited by applicant]
US 20160338407A1 · Kerdemelidis · 2016 [cited by applicant]
US 20160345621A1 · Li et al. · 2016 [cited by applicant]
US 20170119040A1 · Cameron · 2017 [cited by applicant]
US 20170119051A1 · Blandino et al. · 2017 [cited by applicant]
US 20170303594A1 · Cameron et al. · 2017 [cited by applicant]
US 20170325494A1 · Cameron et al. · 2017 [cited by applicant]
US 20180071274A1 · Havercroft et al. · 2018 [cited by applicant]
US 20180199618A1 · Fuisz et al. · 2018 [cited by applicant]
US 20180279667A1 · Mcadam et al. · 2018 [cited by applicant]
US 20180304031A1 · Havercroft et al. · 2018 [cited by applicant]
US 20190116863A1 · Dull · 2019 [cited by applicant]
US 20200315241A1 · Rubenstein · 2020 [cited by examiner]
US 20200345058A1 · Bowen · 2020 [cited by examiner]
US 20210196700A1 · Nolan et al. · 2021 [cited by applicant]
US 20220132906A1 · Mcadam et al. · 2022 [cited by applicant]
US 20230165299A1 · Cabot · 2023 [cited by applicant]
US 20230180818A1 · Cabot · 2023 [cited by applicant]
US 20230270154A1 · Cabot · 2023 [cited by applicant]
AU 6195998A · 1998 [cited by applicant]
AU 17600B2 · 2000 [cited by applicant]
AU 2019276357A1 · 2020 [cited by applicant]
AU 2019371079B2 · 2022 [cited by applicant]
CN 1708241A · 2005 [cited by applicant]
CN 101390659A · 2009 [cited by applicant]
CN 101404902A · 2009 [cited by applicant]
CN 101583354A · 2009 [cited by applicant]
CN 201375023Y · 2010 [cited by applicant]
CN 102753047A · 2012 [cited by applicant]
CN 104585866A · 2015 [cited by applicant]
CN 104970445A · 2015 [cited by applicant]
CN 105029677A · 2015 [cited by applicant]
CN 105979805A · 2016 [cited by applicant]
CN 106413697A · 2017 [cited by applicant]
CN 106572706A · 2017 [cited by applicant]
CN 107105756A · 2017 [cited by applicant]
CN 107529828A · 2018 [cited by applicant]
CN 107949284A · 2018 [cited by applicant]
CN 108289496A · 2018 [cited by applicant]
CN 108323827A · 2018 [cited by applicant]
DE 102015117811 · 2017 [cited by applicant]
EP 2110033A1 · 2009 [cited by applicant]
EP 2316286A1 · 2011 [cited by applicant]
EP 2340729A1 · 2011 [cited by applicant]
EP 2842640A1 · 2015 [cited by applicant]
EP 3574902 · 2019 [cited by applicant]
GB 2569940 · 2019 [cited by applicant]
GB 2569940A · 2019 [cited by applicant]
JP H03277265A · 1991 [cited by applicant]
JP H0462094U · 1992 [cited by applicant]
JP H1189551A · 1999 [cited by applicant]
JP 2004298331A · 2004 [cited by applicant]
JP 2005511178A1 · 2005 [cited by applicant]
JP 2005533770A · 2005 [cited by applicant]
JP 2009525746A · 2009 [cited by applicant]
JP 2009537120A · 2009 [cited by applicant]
JP 2010516243A · 2010 [cited by applicant]
JP 2012210223A · 2012 [cited by applicant]
JP 2014526240A · 2014 [cited by applicant]
JP 2016073307A · 2016 [cited by applicant]
JP 2016526873A · 2016 [cited by applicant]
JP 2017523785A · 2017 [cited by applicant]
JP 2017536816A · 2017 [cited by applicant]
JP 2021523256A · 2021 [cited by applicant]
JP 2021526147A · 2021 [cited by applicant]
JP 2022506068A · 2022 [cited by applicant]
JP 2022506094A · 2022 [cited by applicant]
KR 20120101118A · 2012 [cited by applicant]
KR 20160008271A · 2016 [cited by applicant]
NZ 536863A · 2007 [cited by examiner]
RU 2048780c1 · 1995 [cited by applicant]
RU 2070062C1 · 1996 [cited by applicant]
RU 2336001C2 · 2008 [cited by applicant]
RU 2536115C2 · 2014 [cited by applicant]
RU 2542547C2 · 2015 [cited by applicant]
RU 2607535C2 · 2017 [cited by applicant]
RU 2653467C2 · 2018 [cited by applicant]
RU 2655188C2 · 2018 [cited by applicant]
RU 2666666C1 · 2018 [cited by applicant]
RU 2736854C1 · 2020 [cited by applicant]
WO 0167819A1 · 2001 [cited by applicant]
WO 03037412A2 · 2003 [cited by applicant]
WO 03049535A1 · 2003 [cited by applicant]
WO 03055486A1 · 2003 [cited by applicant]
WO 03101454A1 · 2003 [cited by applicant]
WO 03103387A2 · 2003 [cited by applicant]
WO 2004060351A2 · 2004 [cited by applicant]
WO 2004076289A2 · 2004 [cited by applicant]
WO 2007091181A2 · 2007 [cited by applicant]
WO 2007138462A2 · 2007 [cited by applicant]
WO 2008069972A2 · 2008 [cited by applicant]
WO 2008069970A3 · 2008 [cited by applicant]
WO 2008146543A1 · 2008 [cited by applicant]
WO 2010045671A1 · 2010 [cited by applicant]
WO 2010107613A1 · 2010 [cited by applicant]
WO 2011045609A1 · 2011 [cited by applicant]
WO 2011079932A1 · 2011 [cited by applicant]
WO 2013034488A2 · 2013 [cited by applicant]
WO 2013068304A1 · 2013 [cited by applicant]
WO 2013161987A1 · 2013 [cited by applicant]
WO 2014140320A1 · 2014 [cited by applicant]
WO 2014187770A2 · 2014 [cited by applicant]
WO 2015006465A1 · 2015 [cited by applicant]
WO 2015009862A3 · 2015 [cited by applicant]
WO 2015177252A1 · 2015 [cited by applicant]
WO 2016020675A1 · 2016 [cited by applicant]
WO 2016071705A1 · 2016 [cited by applicant]
WO 2016096745A1 · 2016 [cited by applicant]
WO 2016115250A1 · 2016 [cited by applicant]
WO 2016145072A1 · 2016 [cited by applicant]
WO 2017103136A1 · 2017 [cited by applicant]
WO 2017175218A2 · 2017 [cited by applicant]
WO 2018023890A1 · 2018 [cited by applicant]
WO 2018064032A1 · 2018 [cited by applicant]
WO 2019086856A1 · 2019 [cited by applicant]
WO 2019086858A1 · 2019 [cited by applicant]
WO 2020089637A1 · 2020 [cited by applicant]
WO 2020089640A1 · 2020 [cited by applicant]
Application and File History for U.S. Appl. No. 14/382,198, filed Aug. 29, 2014, inventors Saleem et al. [cited by applicant]
British and European Pharmacopoeia 6.0, “2.9.31 Particle Size Analysis By Laser Light Diffraction,” British Pharmacopoeia Commission (2014), Stationery Office and Council of Europe (2013), pp. 311-314. [cited by applicant]
Clayton P.M., et al., “Spectroscopic Investigations into the Acid-Base Properties of Nicotine at Different Temperatures,” Analytical Methods, 2013, vol. 5, pp. 81-88. [cited by applicant]
Davies, et al., “Metallic Foams: Their Production, Properties and Applications,” Journal of Materials Science, 1983, vol. 18(7), pp. 1899-1911. [cited by applicant]
Examination Report No. 2 for Australian Application No. 2019370810, mailed on Jun. 15, 2022, 4 pages. [cited by applicant]
First Office Action and Search Report for Chinese Patent Application No. 2019800769594, mailed on Mar. 8, 2022, 14 pages. [cited by applicant]
First Office Action and Search Report for Chinese Patent Application No. 2019800779026, mailed on Mar. 28, 2022, 9 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/AT2011/000123, mailed Sep. 20, 2012, 6 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/GB2019/053094, mailed on Nov. 25, 2020, 6 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2013/057539, mailed on Feb. 11, 2014, 16 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/GB2019/053092, mailed on Feb. 4, 2020, 10 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/GB2019/053094, mailed on Feb. 4, 2020, 14 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/GB2019/053095, mailed on Feb. 4, 2020, 13 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/AT2011/000123, mailed on Jul. 18, 2011, 8 pages. [cited by applicant]
Notice of Acceptance mailed Mar. 23, 2022 for Australian Patent Application No. 2019370808, 3 pages. [cited by applicant]
Office Action mailed Sep. 29, 2015 for Japanese Application No. 2015-506185 filed Apr. 11, 2013, 5 pages. [cited by applicant]
Office Action and Search Report for Chinese Application No. 201980069806.7, mailed on Feb. 9, 2022, 20 pages. [cited by applicant]
Office Action and Search Report mailed Dec. 8, 2021 for Russian Application No. 2021112089, 15 pages. [cited by applicant]
Office Action for Chinese Application No. 201980075317.2., mailed on Feb. 23, 2022, 9 pages. [cited by applicant]
Office Action for Chinese Application No. 201980075317.2., mailed on Jun. 29, 2022, 18 pages. [cited by applicant]
Office Action for Japanese Application No. 2021-522532, mailed on Jul. 26, 2022, 10 pages. [cited by applicant]
Office Action for Japanese Application No. 2021-523220, mailed on Aug. 2, 2022, 13 pages. [cited by applicant]
Office Action for Japanese Application No. 2021-523226, mailed on Jul. 26, 2022, 13 pages. [cited by applicant]
Search Report for Japanese Application No. 2021-522532, mailed Jul. 20, 2022, 58 pages. [cited by applicant]
Search Report for Russian Application No. 2021112073 mailed on Dec. 14, 2021, 2 pages. [cited by applicant]
Search Report for Russian Application No. 2021112078 mailed on Jan. 26, 2022, 3 pages. [cited by applicant]
Search Report mailed Oct. 15, 2014 for Japanese Application No. 2012-556343, 18 pages. [cited by applicant]
Warrier M., et al., “Effect of the Porous Structure of Graphite on Atomic Hydrogen Diffusion and Inventory,” Nucl. Fusion, vol. 47, 2007, pp. 1656-1663. [cited by applicant]
International Search Report and Written Opinion for PCT/GB2019/053084 date mailed Feb. 4, 2020. [cited by applicant]
“Decision of Refusal received for Japanese Patent Application No. 2021-522532, mailed on Jan. 4, 2023”, 8 pages (4 pages of English Translation and 4 pages of Official Copy). [cited by applicant]
“Decision of Refusal received for Japanese Patent Application No. 2021-523256, mailed on Feb. 21, 2023”, 8 pages (4 pages of English Translation and 4 pages of Official Copy). [cited by applicant]
“International Preliminary Report on Patentability received for PCT Patent Application No. PCT/GB2019/053084, mailed on May 14, 2021”, 8 Pages. [cited by applicant]
“International Preliminary Report on Patentability received for PCT Patent Application No. PCT/GB2019/053092, mailed on May 14, 2021”, 7 Pages. [cited by applicant]
“International Preliminary Report on Patentability received for PCT Patent Application No. PCT/GB2019/053095, mailed on May 14, 2021”, 7 Pages. [cited by applicant]
“Notice of Allowance received for Chinese Patent Application No. 201980076959.4, mailed on Sep. 5, 2022”, 6 pages (2 pages of English Translation and 4 pages of Official Copy). [cited by applicant]
“Notice of Reasons for Refusal received for Japanese Patent Application No. 2021-523226 mailed on Feb. 21, 2023”, 8 pages (4 pages of English Translation and 4 pages of Official Copy). [cited by applicant]
“Office Action received for Canadian Patent Application No. 3,118,059, mailed on Jun. 15, 2023”, 5 pages. [cited by applicant]
“Office Action received for Japanese Patent Application No. 2021-523256, mailed on Jul. 26, 2020”, 13 pages (6 pages of English Translation and 7 pages of Official Copy of Search Copy). [cited by applicant]
“Report of Reconsideration by Examiner before Appeal for Japanese Patent Application No. 2021-522532, dated Jun. 13, 2023”, 5 pages (2 pages of English Translation and 3 pages of Official Copy). [cited by applicant]
“Search Report for Russian Application No. 2021112009, mailed Dec. 27, 2021”, 2 pages (Official Copy Only). [cited by applicant]
Martin , et al., “Nebulizers for Drug Delivery to the Lungs”, Expert Opinion on Drug Delivery, vol. 12, No. 6, Dec. 2014, pp. 889-900. [cited by applicant]
Shekunov , et al., “Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications”, Pharmaceutical Research, vol. 24, No. 2, Feb. 2007, pp. 203-227. [cited by applicant]
Office Action issued on Dec. 27, 2017 for U.S. Appl. No. 14/927,556. [cited by applicant]